ECUR 506
Alternative Names: ECUR-506; GTP-506; iECURE-OTCLatest Information Update: 13 Jan 2026
At a glance
- Originator iECURE
- Class Gene therapies
- Mechanism of Action Gene transference; Ornithine carbamoyltransferase replacements
-
Orphan Drug Status
Yes - Ornithine carbamoyltransferase deficiency disease
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Ornithine carbamoyltransferase deficiency disease
Most Recent Events
- 07 Jan 2026 ECUR 506 receives an Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP)
- 07 Jan 2026 ECUR 506 receives Regenerative Medicine Advanced Therapy (RMAT) status for Ornithine carbamoyltransferase deficiency disease in USA
- 07 Jan 2026 iECURE announces intention to submit BLA to the US FDA for Ornithine carbamoyltransferase deficiency disease